patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_168761 | REC_0001901 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 8.1 | 67 | female | 0 | 33 | 5.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.6 | true | MSS | 2026-03-15T05:35:57.313654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293432 | REC_0001902 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 10.4 | 68 | female | 1 | 19 | 3.5 | 6 | entrectinib 600 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:35:57.313887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874276 | REC_0001903 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 11.1 | 74 | female | 1 | 12 | 5 | 7 | sotorasib 960 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:57.314121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481744 | REC_0001904 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 16.6 | 69 | female | 1 | 5 | 4.8 | 2 | osimertinib 80 mg daily | 23.9 | false | MSS | 2026-03-15T05:35:57.314354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311388 | REC_0001905 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 8.7 | 69 | male | 0 | 6 | 6.5 | 5 | osimertinib 80 mg daily | 18.6 | false | MSS | 2026-03-15T05:35:57.314587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848445 | REC_0001906 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 9.8 | 55 | male | 0 | 16 | 5.3 | 1 | osimertinib 80 mg daily | 20.4 | false | MSS | 2026-03-15T05:35:57.314820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752884 | REC_0001907 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 10.6 | 65 | female | 0 | 21 | 5.3 | 5 | sotorasib 960 mg daily | 7 | true | MSI-H | 2026-03-15T05:35:57.315056+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729580 | REC_0001908 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 13.2 | 69 | female | 0 | 10 | 5.7 | 8 | pembrolizumab 200 mg q3w | 14.5 | false | MSI-H | 2026-03-15T05:35:57.315287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623138 | REC_0001909 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 14.3 | 66 | female | 0 | 14 | 8 | 2 | sotorasib 960 mg daily | 19.7 | false | MSS | 2026-03-15T05:35:57.315519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647979 | REC_0001910 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 17.5 | 71 | female | 2 | 23 | 3.6 | 5 | osimertinib 80 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:35:57.315751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518863 | REC_0001911 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 6.2 | 48 | male | 0 | 10 | 8 | 5 | alectinib 600 mg BID | 11.7 | true | MSS | 2026-03-15T05:35:57.315982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_531182 | REC_0001912 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 8.4 | 73 | female | 2 | 22 | 4.9 | 8 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:35:57.316355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583920 | REC_0001913 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.1 | 77 | female | 1 | 85 | 5.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.2 | false | MSS | 2026-03-15T05:35:57.316592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187419 | REC_0001914 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 11.3 | 70 | male | 2 | 18 | 3.6 | 1 | alectinib 600 mg BID | 26.2 | false | MSS | 2026-03-15T05:35:57.316833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357955 | REC_0001915 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 7.9 | 74 | female | 0 | 16 | 6.7 | 2 | osimertinib 80 mg daily | 22.4 | false | MSS | 2026-03-15T05:35:57.317067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410273 | REC_0001916 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 8.7 | 74 | female | 1 | 20 | 6 | 3 | osimertinib 80 mg daily | 9.9 | true | MSS | 2026-03-15T05:35:57.317295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173007 | REC_0001917 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 36 | 11.8 | 68 | female | 1 | 19 | 6 | 6 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:57.317524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272298 | REC_0001918 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 12.5 | 73 | female | 1 | 18 | 4.2 | 6 | pembrolizumab 200 mg q3w | 14.8 | false | MSS | 2026-03-15T05:35:57.317759+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132557 | REC_0001919 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 13 | 64 | female | 0 | 15 | 7.3 | 1 | alectinib 600 mg BID | 16.2 | false | MSI-H | 2026-03-15T05:35:57.317996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294092 | REC_0001920 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14.1 | 63 | male | 0 | 25 | 6.5 | 8 | osimertinib 80 mg daily | 7.6 | true | MSS | 2026-03-15T05:35:57.318229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_689954 | REC_0001921 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 21.3 | 78 | female | 1 | 10 | 6.1 | 4 | sotorasib 960 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:57.318460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449255 | REC_0001922 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 17 | 6.4 | 67 | female | 1 | 13 | 4.7 | 2 | pembrolizumab 200 mg q3w | 22.1 | true | MSS | 2026-03-15T05:35:57.318695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927119 | REC_0001923 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 6 | 81 | male | 0 | 40 | 5.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.4 | false | MSS | 2026-03-15T05:35:57.318944+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884564 | REC_0001924 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 12.9 | 71 | female | 0 | 23 | 5.1 | 2 | alectinib 600 mg BID | 21.6 | true | MSI-H | 2026-03-15T05:35:57.319195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167568 | REC_0001925 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 31 | 14.4 | 68 | male | 1 | 20 | 5.9 | 2 | pembrolizumab 200 mg q3w | 28.6 | false | MSS | 2026-03-15T05:35:57.319549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286473 | REC_0001926 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 4.5 | 74 | female | 2 | 24 | 6.3 | 7 | pembrolizumab 200 mg q3w | 9.4 | true | MSS | 2026-03-15T05:35:57.319812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842848 | REC_0001927 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 8.5 | 75 | female | 1 | 24 | 4.1 | 2 | entrectinib 600 mg daily | 18.2 | false | MSS | 2026-03-15T05:35:57.320055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556304 | REC_0001928 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 2.3 | 60 | male | 1 | 20 | 4.8 | 2 | alectinib 600 mg BID | 24.2 | false | MSS | 2026-03-15T05:35:57.320435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970701 | REC_0001929 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 22.1 | 59 | female | 1 | 14 | 3.9 | 7 | alectinib 600 mg BID | 12.3 | false | MSS | 2026-03-15T05:35:57.320680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_665791 | REC_0001930 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 14 | 73 | female | 2 | 12 | 6.4 | 3 | sotorasib 960 mg daily | 17.7 | true | MSS | 2026-03-15T05:35:57.320915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936856 | REC_0001931 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 5.2 | 76 | female | 1 | 66 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.6 | true | MSS | 2026-03-15T05:35:57.321149+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441940 | REC_0001932 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 11.2 | 78 | female | 2 | 18 | 5.7 | 8 | sotorasib 960 mg daily | 16.7 | false | MSI-H | 2026-03-15T05:35:57.321385+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277251 | REC_0001933 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.3 | 58 | female | 0 | 6 | 5.6 | 4 | osimertinib 80 mg daily | 4.3 | true | MSI-H | 2026-03-15T05:35:57.321621+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_942283 | REC_0001934 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 35 | 11.6 | 67 | female | 0 | 8 | 3.2 | 2 | osimertinib 80 mg daily | 14.8 | true | MSS | 2026-03-15T05:35:57.321856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893583 | REC_0001935 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 19 | 12.2 | 60 | female | 0 | 16 | 4.9 | 0 | sotorasib 960 mg daily | 54.8 | false | MSI-H | 2026-03-15T05:35:57.322094+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_689676 | REC_0001936 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 8.3 | 62 | male | 1 | 14 | 4.5 | 2 | alectinib 600 mg BID | 24.5 | false | MSS | 2026-03-15T05:35:57.322327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980918 | REC_0001937 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 19.2 | 77 | female | 2 | 17 | 4.6 | 4 | pembrolizumab 200 mg q3w | 9.6 | false | MSS | 2026-03-15T05:35:57.322563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474474 | REC_0001938 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 17.1 | 72 | male | 1 | 15 | 5.2 | 5 | osimertinib 80 mg daily | 8.5 | false | MSS | 2026-03-15T05:35:57.322882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434825 | REC_0001939 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 7.5 | 68 | male | 0 | 16 | 6.4 | 1 | osimertinib 80 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:57.323122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321529 | REC_0001940 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 19.7 | 63 | female | 1 | 21 | 5.4 | 5 | alectinib 600 mg BID | 15.3 | false | MSI-H | 2026-03-15T05:35:57.323357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812162 | REC_0001941 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 12.5 | 66 | female | 1 | 25 | 6 | 4 | osimertinib 80 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:35:57.323594+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952919 | REC_0001942 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 12.2 | 45 | female | 0 | 35 | 5.7 | 3 | entrectinib 600 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:57.323827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358592 | REC_0001943 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 11.7 | 75 | female | 1 | 19 | 6.1 | 1 | osimertinib 80 mg daily | 16.6 | false | MSI-H | 2026-03-15T05:35:57.324063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823057 | REC_0001944 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 11.2 | 60 | male | 0 | 22 | 5.5 | 7 | sotorasib 960 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:57.324351+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739332 | REC_0001945 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 7 | 78 | female | 2 | 62 | 4.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.5 | true | MSS | 2026-03-15T05:35:57.324582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542287 | REC_0001946 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.8 | 71 | female | 3 | 9 | 4 | 6 | osimertinib 80 mg daily | 6.9 | true | MSS | 2026-03-15T05:35:57.324818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664807 | REC_0001947 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 10.4 | 80 | female | 1 | 15 | 7.1 | 2 | entrectinib 600 mg daily | 25.7 | true | MSI-H | 2026-03-15T05:35:57.325050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291850 | REC_0001948 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 5.5 | 64 | female | 0 | 7 | 7.8 | 4 | osimertinib 80 mg daily | 11.6 | true | MSS | 2026-03-15T05:35:57.325281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592078 | REC_0001949 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 7.1 | 71 | female | 0 | 10 | 4.8 | 1 | alectinib 600 mg BID | 12.8 | false | MSS | 2026-03-15T05:35:57.325512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977538 | REC_0001950 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 5.9 | 61 | female | 0 | 86 | 3.3 | 4 | pembrolizumab 200 mg q3w | 13.7 | false | MSS | 2026-03-15T05:35:57.325742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850967 | REC_0001951 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 11.8 | 80 | female | 2 | 10 | 5.4 | 2 | sotorasib 960 mg daily | 16.7 | false | MSS | 2026-03-15T05:35:57.326023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497724 | REC_0001952 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 5.1 | 64 | female | 1 | 3 | 6.8 | 1 | entrectinib 600 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:57.326259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427102 | REC_0001953 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 14.6 | 73 | male | 2 | 0 | 4.5 | 5 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:57.326495+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112246 | REC_0001954 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 13.9 | 62 | female | 0 | 9 | 6.2 | 8 | sotorasib 960 mg daily | 19.6 | true | MSS | 2026-03-15T05:35:57.326733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168578 | REC_0001955 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11.4 | 59 | male | 1 | 23 | 6.8 | 4 | alectinib 600 mg BID | 9.7 | false | MSI-H | 2026-03-15T05:35:57.326967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242757 | REC_0001956 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 13 | 64 | male | 1 | 19 | 4 | 5 | sotorasib 960 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:57.327202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854040 | REC_0001957 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 7.2 | 67 | female | 0 | 14 | 7.5 | 2 | entrectinib 600 mg daily | 22.4 | false | MSS | 2026-03-15T05:35:57.327433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758116 | REC_0001958 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 10 | 69 | female | 1 | 17 | 5.1 | 2 | osimertinib 80 mg daily | 22.9 | true | MSS | 2026-03-15T05:35:57.327665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_595660 | REC_0001959 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 3.4 | 68 | male | 1 | 8 | 4.7 | 2 | pembrolizumab 200 mg q3w | 27.8 | true | MSS | 2026-03-15T05:35:57.327898+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404765 | REC_0001960 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 5.7 | 71 | female | 1 | 18 | 3.3 | 2 | osimertinib 80 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:57.328178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129699 | REC_0001961 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 10.1 | 75 | female | 2 | 7 | 5.1 | 3 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.328416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_718449 | REC_0001962 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 13.2 | 72 | female | 2 | 17 | 4.6 | 7 | alectinib 600 mg BID | 9.8 | true | MSI-H | 2026-03-15T05:35:57.328651+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709866 | REC_0001963 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 6.5 | 51 | female | 0 | 44 | 7.5 | 6 | pembrolizumab 200 mg q3w | 5.4 | true | MSS | 2026-03-15T05:35:57.328883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968802 | REC_0001964 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 8.2 | 71 | female | 1 | 36 | 5.6 | 7 | pembrolizumab 200 mg q3w | 12.3 | false | MSS | 2026-03-15T05:35:57.329158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769597 | REC_0001965 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 20 | 5.4 | 64 | male | 0 | 12 | 6.6 | 0 | pembrolizumab 200 mg q3w | 32 | false | MSS | 2026-03-15T05:35:57.329393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980506 | REC_0001966 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 5.7 | 55 | female | 1 | 33 | 7.2 | 8 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:57.329624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317568 | REC_0001967 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.5 | 53 | female | 0 | 19 | 6.2 | 5 | alectinib 600 mg BID | 12.4 | false | MSI-H | 2026-03-15T05:35:57.329861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325279 | REC_0001968 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 9.3 | 63 | female | 0 | 26 | 4.6 | 2 | osimertinib 80 mg daily | 20.2 | false | MSS | 2026-03-15T05:35:57.330093+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_666838 | REC_0001969 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 4.7 | 85 | female | 1 | 19 | 5.6 | 8 | osimertinib 80 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:57.330321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757143 | REC_0001970 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 9.4 | 58 | male | 0 | 8 | 5.3 | 2 | entrectinib 600 mg daily | 22.8 | false | MSS | 2026-03-15T05:35:57.330552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562085 | REC_0001971 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 16 | 65 | male | 0 | 11 | 6.2 | 3 | osimertinib 80 mg daily | 14.3 | true | MSI-H | 2026-03-15T05:35:57.330786+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986014 | REC_0001972 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 12.9 | 78 | male | 0 | 19 | 5 | 6 | alectinib 600 mg BID | 8.9 | false | MSI-H | 2026-03-15T05:35:57.331019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722792 | REC_0001973 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 15.8 | 85 | male | 1 | 17 | 4.2 | 2 | osimertinib 80 mg daily | 14.3 | true | MSI-H | 2026-03-15T05:35:57.331256+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673045 | REC_0001974 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 17.8 | 62 | male | 1 | 30 | 3.7 | 6 | osimertinib 80 mg daily | 8.3 | true | MSS | 2026-03-15T05:35:57.331486+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247174 | REC_0001975 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 26 | 6.8 | 63 | female | 1 | 56 | 6 | 0 | carboplatin + paclitaxel + pembrolizumab | 14.1 | false | MSS | 2026-03-15T05:35:57.331718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699420 | REC_0001976 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 8.8 | 71 | female | 1 | 11 | 7.3 | 1 | entrectinib 600 mg daily | 8.5 | false | MSS | 2026-03-15T05:35:57.331947+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598633 | REC_0001977 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 15.1 | 70 | female | 1 | 18 | 3 | 4 | osimertinib 80 mg daily | 13.3 | true | MSI-H | 2026-03-15T05:35:57.332276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840510 | REC_0001978 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 12.6 | 64 | female | 1 | 24 | 6.5 | 6 | sotorasib 960 mg daily | 8.5 | false | MSS | 2026-03-15T05:35:57.332519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487525 | REC_0001979 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 7.1 | 59 | male | 1 | 25 | 4.3 | 7 | pembrolizumab 200 mg q3w | 13.4 | true | MSS | 2026-03-15T05:35:57.332753+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601068 | REC_0001980 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 13.2 | 64 | female | 1 | 14 | 3 | 8 | alectinib 600 mg BID | 7.3 | true | MSI-H | 2026-03-15T05:35:57.332988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307320 | REC_0001981 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 7.3 | 40 | male | 0 | 19 | 5.2 | 6 | sotorasib 960 mg daily | 12.7 | true | MSS | 2026-03-15T05:35:57.333217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430076 | REC_0001982 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 8.9 | 62 | male | 0 | 11 | 5.6 | 6 | osimertinib 80 mg daily | 7 | false | MSS | 2026-03-15T05:35:57.333447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411182 | REC_0001983 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 3.1 | 59 | female | 0 | 27 | 5.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.3 | false | MSS | 2026-03-15T05:35:57.333680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571106 | REC_0001984 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 8.3 | 71 | female | 1 | 18 | 6.5 | 2 | alectinib 600 mg BID | 15.8 | true | MSS | 2026-03-15T05:35:57.333913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700238 | REC_0001985 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 4.1 | 56 | female | 1 | 16 | 5.8 | 5 | sotorasib 960 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:57.334145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_120387 | REC_0001986 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 7.6 | 77 | female | 2 | 20 | 8 | 4 | entrectinib 600 mg daily | 10.8 | false | MSS | 2026-03-15T05:35:57.334379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802945 | REC_0001987 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.4 | 82 | female | 1 | 62 | 4.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.9 | true | MSS | 2026-03-15T05:35:57.334606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150710 | REC_0001988 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 5.4 | 53 | female | 0 | 11 | 6 | 4 | osimertinib 80 mg daily | 7.3 | true | MSS | 2026-03-15T05:35:57.334836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754496 | REC_0001989 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 17.2 | 65 | female | 0 | 20 | 7.3 | 6 | alectinib 600 mg BID | 5.6 | true | MSS | 2026-03-15T05:35:57.335073+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_694251 | REC_0001990 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 9.5 | 55 | female | 1 | 5 | 5.1 | 4 | alectinib 600 mg BID | 6.5 | true | MSS | 2026-03-15T05:35:57.335349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944107 | REC_0001991 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 19.7 | 61 | female | 0 | 2 | 6.9 | 7 | entrectinib 600 mg daily | 7.8 | true | MSI-H | 2026-03-15T05:35:57.335589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868546 | REC_0001992 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 10 | 70 | male | 2 | 11 | 4.1 | 8 | sotorasib 960 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:57.335826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_661905 | REC_0001993 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 15.3 | 72 | female | 1 | 14 | 5.8 | 1 | entrectinib 600 mg daily | 16.2 | true | MSS | 2026-03-15T05:35:57.336058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707286 | REC_0001994 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 6.5 | 66 | female | 1 | 13 | 2.1 | 1 | entrectinib 600 mg daily | 17.6 | false | MSS | 2026-03-15T05:35:57.336369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617328 | REC_0001995 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 9.6 | 61 | female | 0 | 17 | 4.2 | 5 | entrectinib 600 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:57.336605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280228 | REC_0001996 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 15.8 | 58 | male | 1 | 11 | 3.2 | 7 | entrectinib 600 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:35:57.336843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276018 | REC_0001997 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 13.1 | 66 | female | 1 | 15 | 5 | 5 | sotorasib 960 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:57.337076+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808336 | REC_0001998 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 10.6 | 58 | female | 0 | 5 | 3.3 | 2 | alectinib 600 mg BID | 7.4 | false | MSS | 2026-03-15T05:35:57.337309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654578 | REC_0001999 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 36 | 12.7 | 66 | male | 1 | 16 | 5.4 | 1 | sotorasib 960 mg daily | 21.9 | true | MSI-H | 2026-03-15T05:35:57.337547+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301648 | REC_0002000 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 13.9 | 69 | female | 0 | 10 | 4.8 | 5 | sotorasib 960 mg daily | 15.5 | false | MSI-H | 2026-03-15T05:35:57.337778+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.